🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — July 13, 2026

The three filings from the S&P 500 Healthcare sector—Edwards Lifesciences, Intuitive Surgical, and Pfizer—reveal a sector dominated by routine insider transactions related to tax withholding and equity compensation, with no overtly bullish or bearish signals. The lack of significant period-over-period comparisons, forward-looking guidance, or capital allocation changes across these filings suggests a quiet period for these companies, with no material shifts in financial health or management outlook. The most notable insider activity is from Intuitive Surgical's CEO, who exercised and had shares withheld for taxes, a common practice that does not indicate a change in conviction. Overall, the sector appears stable with no immediate catalysts or red flags from these specific filings, though the absence of strong signals may imply a wait-and-see approach for investors.

3 high priority 3 total filings
· daily

US Earnings Financial Results SEC Filings — July 13, 2026

The 12 filings reveal a bifurcated landscape: pre-revenue and early-stage companies (Lexaria, SolarWindow, Lantics, Apex 11, Jubilant Flame) continue to burn cash with widening losses, while a few entities show operational turnarounds (Solitron Devices, Iron Horse Acquisition II) or revenue growth (Onar Holding). The most striking portfolio-level trend is the severe cash burn and asset depletion across micro-cap names—Crypto Co's assets collapsed 85%, Onar's cash dropped 88%, and multiple companies (Apex 11, Jubilant Flame, Lantics) have near-zero cash positions, signaling imminent financing needs or going-concern risks. On the positive side, Solitron Devices posted a remarkable 101% revenue surge and swung to a $990K profit from a $336K loss, while Iron Horse and XFLH Capital (SPACs) generated substantial trust account interest income. Insider trading activity was notably absent across all filings, which is a neutral signal but warrants monitoring. Capital allocation is minimal—no dividends or buybacks—with most companies relying on equity or debt financing. The forward-looking data is sparse, but the scheduled events (earnings calls for Solitron, BAB, and others) provide near-term catalysts. Overall, the digest highlights extreme risk in pre-revenue micro-caps and selective turnaround opportunities in niche industrials and SPACs.

12 high priority 12 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 13, 2026

This batch of 11 proxy filings reveals a market dominated by transformative corporate actions, including two major mergers (AvalonBay/Equity Residential and Huntsman/Olin) and a high-premium biotech acquisition (Apogee Therapeutics at a 53% premium). A notable trend is the prevalence of corporate governance and structural changes, with Weatherford International redomesticating from Ireland to Delaware, Sphere 3D moving from Ontario to British Columbia, and Faraday Future undergoing a CEO shake-up while seeking shareholder approval for a dilutive convertible note conversion. Insider ownership patterns are mixed: while SharonAI Holdings shows concentrated insider control (45.94% voting power), Faraday Future's executives and directors collectively own less than 1% of shares, signaling a significant misalignment of interests. Period-over-period comparisons are limited in these filings, but the financial data available points to operational stress at Huntsman and Olin, both reporting net losses in 2025. The overall sentiment is neutral to mixed, with the most actionable intelligence centered on the merger arbitrage opportunities in the AvalonBay/Equity Residential and Apogee deals, and the governance risks at Faraday Future and Weatherford.

11 high priority 11 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 13, 2026

The IPO pipeline is active with four new S-1 filings, highlighting a mix of healthcare technology, industrial laser, and SPAC offerings. The filings reveal a cautious market sentiment, with two companies (Nuburu and N2OFF) showing significant ongoing losses and negative sentiment, while Avalon GloboCare and Material Resource Acquisition Corp. present neutral profiles. Period-over-period data is limited, but N2OFF's pro forma financials show a net loss of $6.841 million with no revenue from its recent acquisition, indicating operational challenges. Insider activity is sparse, but management changes at Avalon GloboCare and complex capital structures at Nuburu and N2OFF signal potential governance and dilution risks. The SPAC offering from Material Resource Acquisition Corp. provides a traditional blank-check structure with a $200 million target, reflecting continued interest in SPACs despite regulatory scrutiny. Overall, the pipeline is weighted towards riskier, early-stage companies, with only the SPAC offering a more conventional investment profile.

4 high priority 4 total filings
· daily

USA Institutional Investor Activity — July 13, 2026

The sole filing in this intelligence stream is a 13F-HR from Parkside Investments, LLC, covering holdings as of June 30, 2026. The filing reveals a portfolio heavily concentrated in fixed-income and preferred-income ETFs, notably ISHARES 1-5 YEAR INVESTMENT GRADE CORPORATE BOND ETF and FIRST TRUST PREFERRED SECURITIES & INCOME ETF, suggesting a defensive, income-oriented strategy. However, the enriched data lacks period-over-period comparisons, insider activity, forward-looking guidance, and capital allocation details, severely limiting trend analysis and actionable insights. Without changes versus prior filings, it is impossible to determine if positions were increased or decreased, making the filing's materiality moderate at best. The neutral sentiment and absence of bullish or bearish signals mean this filing offers no clear directional intelligence for institutional investor activity. As a result, this digest is constrained, and the filing is best treated as a data point for monitoring rather than a source of immediate investment signals.

1 medium 1 total filings
· daily

US SEC Trading Suspension Halt Orders — July 13, 2026

Three US-listed micro-cap companies received Nasdaq delisting or suspension notices on July 7-10, 2026, underscoring a severe liquidity and compliance crisis in the small-cap space. Pluri Inc. (PLUR) faces a market value deficiency with a cure period through January 4, 2027, while Actelis Networks (ASNS) has already been suspended and moved to OTCQB, and BNB Plus Corp. (BNBX) will be suspended July 14. All three filings carry negative sentiment and high materiality (9-10/10), with no insider buying, no forward guidance, and no capital allocation actions (dividends/buybacks) reported—indicating distressed balance sheets. The cluster of delistings within a single week suggests heightened regulatory scrutiny on minimum listing standards, particularly for companies with market caps below $35 million. Investors should monitor the OTCQB transition for potential price discovery dislocations and short-squeeze dynamics, while avoiding long exposure until compliance is restored.

3 high priority 3 total filings
· daily

US Executive Officer Management Changes SEC — July 13, 2026

This digest of 31 SEC filings reveals a significant wave of C-suite and board-level transitions, with a notable trend of internal promotions and orderly successions. Key themes include the departure of CEOs at Shutterstock and Brown-Forman triggering strategic reviews, and a CFO transition at CoStar Group where an internal candidate with a proven track record of cost reduction is promoted. A critical governance risk flag is raised by the resignation of a Fermi Inc. director over a disputed $350 million convertible bond issuance, signaling potential internal control issues. While most changes are non-contentious, the sheer volume of leadership shifts, including new CFOs at Workhorse, Klaviyo, and MBX Biosciences, suggests a period of strategic repositioning across multiple sectors. The data shows a clear preference for promoting internal talent or appointing executives with deep industry experience, which generally signals stability. However, the lack of disclosed financial metrics in many filings limits the ability to assess the immediate financial impact of these changes.

31 high priority 31 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 13, 2026

The July 13, 2026, board room changes stream reveals a high volume of leadership transitions across 31 filings, with a notable cluster of CEO and CFO departures in the technology and life sciences sectors. Key themes include orderly succession planning at companies like Brown-Forman and Klaviyo, contrasted with a contentious director resignation at Fermi Inc. over governance concerns. While most changes are routine, the data highlights a significant number of CFO and C-suite exits, including at CoStar Group, Shutterstock, and MBX Biosciences, suggesting a period of strategic realignment. Insider trading activity is sparse in these filings, but forward-looking statements from Brown-Forman (reiterated FY2027 outlook) and Klaviyo (planned CFO transition with advisory period) provide stability signals. The most critical development is the Fermi Inc. director resignation, which raises governance red flags and warrants close monitoring.

31 high priority 31 total filings
· daily

USA Insider Trading Pulse — July 13, 2026

Today's insider trading filings reveal a pronounced divergence between high-conviction insider buying and large-scale disposals, primarily through option exercises and share-for-tax withholdings. The most notable bullish signal is a $2.18M open-market purchase by Dreamland Ltd's CEO, signaling strong management confidence. Conversely, a massive $401M sale by a SharkNinja director and a $294M sale by United Microelectronics Corp's CFO raise significant caution flags. A cluster of 'disposed to issuer' transactions at Esperion Therapeutics, totaling over 4 million shares from top executives, suggests a major corporate restructuring or buyout event. Sector-wise, insider selling is concentrated among tech and growth names, while value-oriented industrials and real estate see insider accumulation. The data also highlights a wave of restricted stock unit vestings and tax-withholding sales, which are less directional but still increase supply. Overall, the pattern points to a cautious but opportunistic market, with select pockets of deep insider conviction.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 13, 2026

Today's M&A digest is dominated by SPAC activity, with 6 of 11 filings involving blank-check companies. The most significant development is the termination of SC II Acquisition Corp.'s LOI with a payments technology target, a high-materiality negative signal that increases the risk of liquidation. In contrast, Tavia Acquisition Corp. announced a non-binding LOI with Vita Inclinata at a $450M pre-money valuation, providing a clear catalyst for a Q4 2026 de-SPAC. The largest transaction by value is Edgewise Therapeutics' $1.55B upfront sale of its muscular dystrophy business to Servier, a transformative deal that fully funds its cardiovascular pipeline through potential approval. Esperion Therapeutics' acquisition by ArchiMed-backed Essence Parent Inc. includes a Contingent Value Rights (CVR) agreement tied to $300M+ in annual net sales milestones, offering a potential upside kicker for former shareholders. Period-over-period data is limited across these filings, but the pro forma financials from Franklin Street Properties show a $1.1M loss on debt extinguishment from a property sale, while Plum Acquisition Corp. III's pro forma balance sheet reveals a $30M inventory adjustment from a crushed aggregate acquisition. The overall theme is a bifurcated SPAC market: some sponsors are securing extensions and targets, while others are failing to close deals, increasing the risk of liquidations.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 13, 2026

Overnight SEC filings from July 12-13, 2026, reveal a market dominated by corporate actions, regulatory shifts, and capital structure changes, with several high-conviction signals for active investors. The most significant development is the forced delisting of Bowen Acquisition Corp (BOWN) from Nasdaq, a stark reminder of SPAC mortality risk. In the financial sector, Patriot National Bancorp's removal of its 'troubled condition' status marks a major turnaround, while XAI Octagon Floating Rate & Alternative Income Trust is embroiled in a proxy fight following severe underperformance. Capital markets are active, with Public Storage issuing $900M in debt to fund an acquisition and Research Alliance Corp IV launching a $75M SPAC IPO. On the earnings front, Onar Holding Corp reported a 39% revenue surge but with deteriorating margins and a precarious cash position, while Royale Energy narrowed its net loss by 42% despite a 14% revenue decline. Insider activity is notable at SharkNinja, where a waiver was granted for a chairman's share sale, and at Lisata Therapeutics, where a tender offer is set to close. Overall, the filings point to a bifurcated market where disciplined capital allocation and regulatory clarity are rewarded, while companies with weak balance sheets or governance issues face increasing scrutiny.

11 high priority 39 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — July 12, 2026

This digest covers a single, large civilian contract awarded to Brasfield & Gorrie LLC by the FBI (Department of Justice) for $147.6 million in commercial construction in Birmingham, AL. The contract is entirely civilian, with no defense exposure, and represents a stable, high-priority federal infrastructure investment. The highest-conviction signal is the firm-fixed-price structure, which provides predictable revenue but also exposes the contractor to execution risk over the three-year performance period. A key watch item is the low initial outlay of only $9.6 million, indicating early-stage execution and potential for significant revenue recognition ahead, but also risk of funding delays under a potential Continuing Resolution.

1 total filings
· daily

New Federal Contractors — July 12, 2026

This digest covers a single, large civilian contract awarded to Brasfield & Gorrie LLC by the FBI (Department of Justice) for $147.6 million in commercial construction. The contract is a firm-fixed-price award with full and open competition, signaling a competitive win in the stable federal construction sector. With only $9.6 million outlaid so far, the contract is in early execution stages, offering predictable but back-loaded revenue recognition. The key risk is execution pace and potential budget delays under a continuing resolution, though FBI infrastructure spending is typically sustained. The highest-conviction signal is the neutral, competitive nature of the award, which provides no clear moat but reduces protest risk.

1 total filings
· daily

Significant Contract Modifications ($10M+) — July 12, 2026

This digest covers a single significant contract modification from July 12, 2026, totaling $147.6 million, entirely civilian (Department of Justice/FBI). The award to Brasfield & Gorrie LLC for commercial construction in Birmingham, AL, is a firm-fixed-price contract with full and open competition, signaling a competitive win in stable federal security infrastructure. The neutral signal (strength 5/10) reflects predictable revenue but early-stage execution risk, with only $9.6 million outlaid. Key watch items include future outlay pace and potential modifications to increase total value.

1 total filings
· daily

Contract Deobligations Alert — July 12, 2026

This digest covers a single $147.6 million contract deobligation from the FBI (Department of Justice) to Brasfield & Gorrie LLC for commercial construction in Birmingham, AL. The contract is entirely civilian (0% defense-related) and represents a competitive, firm-fixed-price award with a medium signal strength of 5/10. The key investment story is a stable, predictable revenue stream for Brasfield & Gorrie over three years, but with only $9.6 million outlaid so far, execution pace and future funding releases are critical to monitor. The dominant theme is sustained federal infrastructure spending for security agencies, though the contract's size relative to Brasfield & Gorrie's overall portfolio is likely modest given the company's large-scale construction focus.

1 total filings
· daily

Contract Option Exercises — July 12, 2026

This digest covers a single $147.6 million contract option exercise from the Department of Justice (FBI) to Brasfield & Gorrie LLC for commercial construction in Birmingham, AL. The contract is entirely civilian (0% defense-related), with a neutral signal strength of 5/10 and a materiality score of 6/10. The highest-conviction signal is the early-stage revenue recognition—only $9.6 million outlaid so far—suggesting most of the $147.6 million will be recognized over the next three years. A key risk is the firm-fixed-price structure, which transfers cost overrun risk to Brasfield & Gorrie, though the stable FBI funding profile mitigates cancellation risk. No bullish or bearish signals were identified, reflecting a routine, competitive award with no set-aside or sole-source dynamics.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 12, 2026

This digest covers a single $147.6 million civilian contract awarded by the FBI to Brasfield & Gorrie LLC for commercial construction in Birmingham, AL, with a performance period through May 2028. The contract is entirely civilian, reflecting stable DOJ/FBI security infrastructure spending, and carries a neutral signal with medium execution risk due to its firm-fixed-price structure and early-stage outlay of only $9.6 million. The highest-conviction signal is the predictable revenue stream over three years, but the key risk is the early-stage execution and potential delays in funding releases. Investors should monitor future outlay amounts and any modifications that could expand total contract value.

1 total filings
· daily

High-Value Federal Grants ($5M+) — July 12, 2026

Today's digest covers a single, large civilian contract: a $147.6 million firm-fixed-price award from the FBI to Brasfield & Gorrie LLC for commercial construction in Birmingham, AL. The contract is 100% civilian (DOJ/FBI), with zero defense exposure, and represents a stable, high-priority security infrastructure project. The highest-conviction signal is neutral: the firm-fixed-price structure provides predictable revenue, but only $9.6 million has been outlaid, indicating early-stage execution and potential revenue recognition risk over the next few years. Key watch items include monitoring future outlay amounts and any modifications or option exercises that could increase total contract value.

1 total filings
· daily

General Federal Contracts — July 12, 2026

Over this single-day period, the digest captures a solitary $147.6 million civilian contract awarded to Brasfield & Gorrie LLC by the FBI (Department of Justice) for commercial construction in Birmingham, AL. This is entirely non-defense, representing zero defense exposure, and carries a neutral signal strength of 5/10. The highest-conviction signal is the contract's firm-fixed-price structure, which provides Brasfield & Gorrie with predictable revenue over the three-year performance period (through May 2028), but the early-stage execution—with only $9.6 million outlaid so far—introduces material revenue recognition risk. The dominant theme is stable, non-tech civilian infrastructure, which offers low growth visibility but low cancellation risk given the FBI's high-priority status.

1 total filings
· daily

Biotech Small-Cap Approvals — July 11, 2026

The July 11, 2026 approval stream is dominated by 5 biosimilar/fallback approvals and 1 NME, presenting a mixed but actionable picture for biotech investors. The standout event is VERA THERAPEUTICS INC.'s NME approval for ATACIEPT-VYMJ (TRUTAKNA) under Priority Review, a clear bullish signal for the sponsor given the high approval bar and expedited review. The remaining 5 approvals are neutral biosimilar entries for established molecules (DESOGESTREL, DIMETHYL SULFOXIDE, MORPHINE SULFATE, VARENICLINE TARTRATE, NITROGLYCERIN) from small-cap sponsors like ANNORA PHARMA, STIRA, QUAGEN, SOMERSET THERAPS LLC, and PADAGIS ISRAEL, which lack disclosed commercial data and face intense generic competition. The key risk is the lack of differentiation and pricing power for these biosimilars, while the primary opportunity is VERA's NME launch trajectory and potential market creation. No dominant therapeutic area theme emerges, but the concentration of biosimilar approvals signals ongoing commoditization in legacy drug markets.

6 total filings